The schizophrenia drug Emraclidine failed to perform in clinical trials but executives say it can still “play a role.” ...

Evolus faces sector instability but shows strong growth potential. Learn why EOLS stock remains a “Buy” despite challenges, ...

AbbVie’s ABBV stock has declined 8% in the past three months. A lot of this price decline is due to the poor performance of ...

AbbVie's strong financials and potential for cash flow make it a valuable investment, despite risks from patent expirations.

Cosmetic Surgery Industry The healthcare landscape in 2025 is poised for a transformative shift, driven by innovation and collaboration< ...

High-yield dividend stocks may not appeal to some investors. However, if you're among those investors looking for income, ...

Baby boomers and users of weight loss drugs suffering from “facial sagging” are flocking to injectable aesthetic treatments ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...

Some prominent healthcare and consumer stocks have fallen out of favor with the market, so now is the time to pounce on some great deals.

AbbVie offers solid growth, an extraordinary dividend, and a long history of success. PepsiCo is in a growth lull right now, but the stock's valuation has fallen too far. Hershey could make ...

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable ...

Being a human being living in 2025 means dealing with stress. And stress often leads to worry. And worry leads to ... wrinkles. Or maybe you’re blessed to have a life full of smiling and laughing, ...